GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma

NCT02499003 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Non-Hodgkin

Interventions

DRUG: Obinutuzumab and Pixantrone

Sponsor

Johannes Gutenberg University Mainz

Collaborators

[object Object]
[object Object]